VIDEO: Some acute myeloid leukemia patients can wait to start treatment
Click Here to Manage Email Alerts
In this video, Catherine Lai, MD, MPH discusses the results of a study presented at ASH Annual Meeting that examined time to treatment initiation in patients with acute myeloid leukemia.
Lai, an assistant professor of clinical medicine at the University of Pennsylvania, highlighted the study, which looked at patients receiving treatment with azacitidine (Onureg, Bristol Myers Squibb) and venetoclax (Venclexta, AbbVie), and tracked whether their time to treatment affected overall survival.
“In clinically stable patients who you think are going to be treated with a hypomethylating agent and venetoclax combination, the recommendation based on this from my perspective is to wait for all your molecular testing.,” Lai said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts